- Global Pharma News & Resources

Jet Injector Markets 2020-2021 & 2026 -

DUBLIN--(BUSINESS WIRE)--The "Jet Injector Market 2020-2026" report has been added to's offering.

The jet injector or needle-free device is a medical device that is used for vaccination and drug delivery by the high-pressure narrow jet of fluid. The major factors that are augmenting the growth of the market include the need for modern technologies in drug delivery technology, the growing prevalence of chronic diseases such as diabetes and cancer among others.

Furthermore, increasing demand for self-injection devices, reduction in risks such as cross-contamination, pain-free devices for patients, and various FDA and government approvals for the needle-free jet injectors are also estimated to be the major factors that are contributing significantly towards the growth of the market. In addition to this, the vaccination for the ongoing COVID-19 pandemic is expected to fuel the market. For Instance, Codagenix's intranasal COVID-19 vaccine does not require the needle to be administered.

However, certain factors are affecting the growth of the market. High development cost, and the need to ensure system sterility are the major constraints that will challenge the growth of the jet injector market across the globe. Conversely, technological advancement and rise in healthcare expenditures with the demand for biosimilar products are opportunities for the market to grow in the forecast period.

Segmental Outlook

The market is segmented on the basis of product, application, technology, and end-user. By product, the market is segmented into prefilled needle-free injectors and fillable needle-free injectors. Based on the application segment, the market is segmented into insulin delivery, respiratory diseases, vaccine delivery, and others. Insulin delivery is expected to hold a major market share during the forecast period.

The market growth is mainly driven by the rise in diabetes across the globe. According to the International Diabetes Federation (IDF), 463 million people globally have diabetes and the low-and middle-income countries are affected more. Moreover, it is one of the leading causes of mortalities across the globe as around 1.6 million mortalities are due to diabetes each year. Therefore, the market is estimated to grow even more in the forecast period due to the rise of the geriatric population.

Further, based on the technology segment, the market is segmented into jet-based, spring-based, laser power-based, and vibration-based. In addition to this, based on the end-user segment, the market is segmented into pharmaceutical companies, hospitals, and clinical centers, and others.

Global Jet Injector Share by Application, 2020 (%)

Regional Outlooks

The global jet injector market is analyzed on the basis of the geographical regions that are contributing significantly to the growth of the market.

North America is estimated to be one of the leading regions in the global jet injector market. Rising demand for self-administration healthcare facilities, mergers, and acquisitions by major players, rise in chronic diseases such as diabetes and cancer, and technological advancement are the major factors that fuel the market growth in North America.

The US accounts for a major share in this region. Asia Pacific is estimated to be one of the fastest-growing regions during the forecast period. The rise in diabetes patients in the countries including India and China and the increase in government funding in this region are the factors that will grow the market in the forecast period. For instance, according to the International Diabetes Federation (IDF), 88 million people had diabetes in the Southeast Asia region out of which 77 million people were of India.

Market Players Outlook

The jet injector market is fragmented however some players are actively contributing to the market. Key players of the jet injector market include European Pharma Group BV, Crossject SA, INJEX Pharma GmbH, and Pharmajet. In order to survive in the market, these players adopt different marketing strategies such as a merger, acquisitions, product launch, and geographical expansion so on.

Key Topics Covered:

1. Report Summary

1.1. Research Methods and Tools

1.2. Market Breakdown

2. Market Overview and Insights

2.1. Scope of the Report

2.2. Analyst Insight & Current Market Trends

2.2.1. Key Findings

2.2.2. Recommendations

2.2.3. Conclusion

3. Competitive Landscape

3.1. Company Share Analysis

3.2. Key Strategy Analysis

3.3. Key Company Analysis

4. Market Determinants

4.1. Motivators

4.2. Restraints

4.3. Opportunities

5. Market Segmentation

5.1. Global Jet Injectors Market, By Product Type

5.1.1. Prefilled Needle-Free Injectors

5.1.2. Fillable Needle-Free Injectors

5.2. Global Jet Injectors Market, By Application

5.2.1. Insulin Delivery

5.2.2. Respiratory Diseases

5.2.3. Vaccine Delivery

5.2.4. Others (Oncology)

5.3. Global Jet Injectors Market, By Technology

5.3.1. Jet Based

5.3.2. Spring Based

5.3.3. Laser Power Based

5.3.4. Vibration Based

5.4. Global Jet Injectors Market, By End-User

5.4.1. Pharmaceutical Companies

5.4.2. Hospital & Clinical Centres

5.4.3. Others

6. Regional Analysis

7. Company Profiles

  • Becton, Dickinson, and Co.
  • European Pharma Group BV
  • Crossject SA
  • INJEX Pharma GmbH
  • Ferring Pharmaceuticals Inc.
  • Enesi Pharma Ltd.
  • Medical International Technology, Inc.
  • Merck KGaA
  • Inovio Pharmaceuticals Inc.
  • PharmaJet, Inc.
  • Mylan NV
  • Spirit Health Group Ltd.
  • Zealand Pharma AS
  • LEO Pharma Inc.
  • Portal Instruments, Inc.

For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Editor Details

  • Company:
    • Businesswire
Last Updated: 07-Jul-2021